Skip to main content

Vaqta Side Effects

Generic name: hepatitis a adult vaccine

Medically reviewed by Drugs.com. Last updated on Dec 6, 2023.

Note: This document contains side effect information about hepatitis a adult vaccine. Some dosage forms listed on this page may not apply to the brand name Vaqta.

Applies to hepatitis a adult vaccine: intramuscular solution, intramuscular suspension.

Serious side effects of Vaqta

Along with its needed effects, hepatitis a adult vaccine (the active ingredient contained in Vaqta) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking hepatitis a adult vaccine:

More common

Rare

Incidence not known

Other side effects of Vaqta

Some side effects of hepatitis a adult vaccine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

Rare

Incidence not known

For Healthcare Professionals

Applies to hepatitis a adult vaccine: intramuscular suspension.

General

The most common adverse events were injection site reactions, irritability, drowsiness, loss of appetite and headache.[Ref]

Local

Very common (10% or more): Injection site soreness (56%), injection site pain (24.3%), injection site redness (22.8%)

Common (1% to 10%): Induration and swelling of the injection site

Uncommon (0.1% to 1%): Injection site hematoma

Postmarketing reports: Injection site reaction[Ref]

Nervous system

Very common (10% or more): Drowsiness (22.3%), headache (14%)

Uncommon (0.1% to 1%): Dysgeusia, hypertonia, vertigo, seizure

Postmarketing reports: Convulsion, dizziness, encephalopathy, Guillain-Barre syndrome, hypoesthesia, multiple sclerosis, myelitis, neuropathy, paresthesia, somnolence, syncope[Ref]

Other

Common (1% to 10%): Fatigue, fever over 99.5F, malaise

Uncommon (0.1% to 1%): Creatine phosphokinase increased

Postmarketing reports: Congenital anomaly, influenza-like symptoms[Ref]

Gastrointestinal

Common (1% to 10%): Nausea

Uncommon (0.1% to 1%): Abdominal pain, diarrhea, vomiting[Ref]

Metabolic

Very common (10% or more): Loss of appetite (19.9%)

Common (1% to 10%): Anorexia[Ref]

Dermatologic

Uncommon (0.1% to 1%): Pruritus, rash, urticaria

Postmarketing reports: Angioedema, erythema multiforme, hyperhidrosis[Ref]

Musculoskeletal

Uncommon (0.1% to 1%): Arthralgia, myalgia

Postmarketing reports: Musculoskeletal stiffness, chills[Ref]

Hematologic

Uncommon (0.1% to 1%): Lymphadenopathy

Postmarketing reports: Thrombocytopenia[Ref]

Immunologic

Uncommon (0.1% to 1%): Pharyngitis, upper respiratory tract infection

Postmarketing reports: Rhinitis[Ref]

Hypersensitivity

Postmarketing reports: Anaphylactic reaction, anaphylactoid reaction, serum sickness-like syndrome[Ref]

Psychiatric

Very common (10% or more): Irritability (33.3%)

Uncommon (0.1% to 1%): Insomnia[Ref]

Hepatic

Postmarketing reports: Hepatitis, jaundice[Ref]

Cardiovascular

Postmarketing reports: Vasculitis[Ref]

Respiratory

Postmarketing reports: Dyspnea[Ref]

Ocular

Uncommon (0.1% to 1%): Photophobia[Ref]

References

1. Product Information. Havrix (HepA) (hepatitis A adult vaccine). SmithKline Beecham. PROD.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.